Component

Human plasma NAD concentration

Context-specific entity; species, compartment and exposure are stated on each claim.

2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. In a randomized pilot with eight NAD+ recipients and three saline controls, 750 mg NAD+ over six hours produced a significant plasma NAD increase at the six-hour endpoint, with no significant early rise during the first two hours.

    Intravenous NAD+ intervention in humans → Human plasma NAD concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary full text
    experimental_model
    Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling.
    limitations
    Small pharmacokinetic study; disappearance from plasma does not prove intact tissue uptake or clinical benefit.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Infusion input and measured blood concentration need not rise together immediately.
    primary_references
    A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 284–290

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling. · source_derived_draft · unverified_draft

    ## nad-plus-iv-plasma Infusion input and measured blood concentration need not rise together immediately. In a randomized pilot with eight NAD+ recipients and three saline controls, 750 mg NAD+ over six hours produced a significant plasma NAD increase at the six-hour endpoint, with no significant early rise during the first two hours. Model: Human pilot; approximately 3 micromoles/minute; serial plasma and urine sampling. Limitations: Small pharmacokinetic study; disappearance from plasma does not prove intact tissue uptake or clinical benefit. Evidence access: Primary full text A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. · 2019 · https://pubmed.ncbi.nlm.nih.gov/31572171/ · DOI 10.3389/fnagi.2019.00257
    Complete structured claim and evidence

  2. The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased.

    LathMized NAD+ formulation → Human plasma NAD concentration source_derived_draftungraded
    Experimental context and source evidence
    availability_state
    biomarker_context Imported condition classification; unverified.
    evidence_access
    Primary abstract
    experimental_model
    Same five-day randomized trial; primary analysis n=50.
    limitations
    Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake.
    nutrient_topic
    NAD+ collection; molecular form, preparation, species, exposure and manipulation remain explicit. · NAD+
    plain_language
    Blood compartments and breakdown products can move differently.
    primary_references
    Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    trigger_kind
    biomarker_context Imported condition classification; unverified.

    NAD+: compartmental supply, consumption and cross-nutrient mechanisms (2026-09-19) · lines 316–322

    AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Same five-day randomized trial; primary analysis n=50. · source_derived_draft · unverified_draft

    ## nad-plus-oral-formulation-plasma Blood compartments and breakdown products can move differently. The same LNAD+ trial found unchanged plasma NAD while methyl-nicotinamide and 2PY increased. Model: Same five-day randomized trial; primary analysis n=50. Limitations: Catabolite concentration changes are consistent with metabolism but are not direct quantitative flux measurements or proof of intact uptake. Evidence access: Primary abstract Oral LNAD+ rapidly elevates whole blood intracellular NAD and metabolic flux without elevating plasma NAD: evidence from a randomized controlled trial. · 2026 · https://pubmed.ncbi.nlm.nih.gov/42530810/ · DOI 10.1007/s11357-026-02399-1
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards